Gilead Sciencesvs.Moderna
GILD vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 5.9× larger than Moderna by market cap; year to date, Moderna leads (+131.5% vs +5.8%).
Side by side
| GILD | MRNA | |
|---|---|---|
| Market cap | $162B | $27.2B |
| Price | $129.83 | $68.27 |
| Today | −3.7% | −10.8% |
| Return YTD | +5.8% | +131.5% |
| Return 1Y | +13.3% | +99.2% |
| P/E | 17.5 | — |
| P/S | 5.4 | 12.2 |
| P/B | 6.9 | 3.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →ModernaMRNA
American biotech company based on mRNA technology — known for the covid vaccine, with a pipeline in vaccines and oncology.
Full MRNA profile →More comparisons in Biotech & innovation
See where GILD and MRNA sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →